Multiple Sclerosis in Mongolia; the First Study Exploring Predictors of Disability and Depression in Mongolian MS Patients

Mongolia is located at 45° north latitude in the center of the Asian continent, and about 80% of the territory is at 1000 m above sea level. Epidemiologically, multiple sclerosis (MS) has not been investigated in Mongolia, although there have been a few MS case reports. We investigated the characteristics of MS in Mongolia for the first time, focusing on the association between MS-related parameters and depression levels. We initiated cross-sectional analyses, using data from 27 MS patients aged 20 to 60 years in Ulaanbaatar, Mongolia. The patients completed a questionnaire on their lifestyles and clinical information. We classified the MS patients on the basis of disability levels using the expanded disability status scale (EDSS) scores: 11.1% mild disability and 88.9% moderate to severe disability (median EDSS score, 5.5). We also classified the patients on the basis of depression levels using the 9-item patient health questionnaire (PHQ-9) scores: 44.4% mild depression, 40.7% moderate depression, and 14.8% severe depression (mean PHQ-9’s score, 9.96 ± 5.05). We used multivariate logistical regression analyses to identify predictors of EDSS or PHQ-9 scores. Disability levels were associated with vision and balance problems. Depression levels were associated with corticosteroid treatment; no patients were treated with disease-modifying drugs (DMDs). The odds ratios for disease onset age and treatment duration were associated with EDSS scores. In conclusion, MS onset age and treatment duration were independent predicting factors influencing the level of disability. Appropriate DMD treatment would lower the disability and depression levels.

[1]  G. Trevisan,et al.  Prevalence of depression and anxiety in the different clinical forms of multiple sclerosis and associations with disability: A systematic review and meta-analysis , 2022, Brain, behavior, & immunity - health.

[2]  F. Mansuri,et al.  Clinical Profile and the Extent of Disability in Multiple Sclerosis Patients in Madinah, Saudi Arabia , 2022, Cureus.

[3]  Basbish Tsogbadrakh,et al.  Frontline Mongolian Healthcare Professionals and Adverse Mental Health Conditions During the Peak of COVID-19 Pandemic , 2022, Frontiers in Psychology.

[4]  A. Martineau,et al.  Prevalence and Determinants of Vitamin D Deficiency in 9595 Mongolian Schoolchildren: A Cross-Sectional Study , 2021, Nutrients.

[5]  S. Hochmeister,et al.  Vitamin D in Multiple Sclerosis—Lessons From Animal Studies , 2021, Frontiers in Neurology.

[6]  Jiquan Chen,et al.  How does mining policy affect rural migration of Mongolia? , 2021 .

[7]  M. Moosazadeh,et al.  Vitamin D status and disability among patients with multiple sclerosis: a systematic review and meta-analysis , 2021, AIMS neuroscience.

[8]  J. Sellner,et al.  A global view of comorbidity in multiple sclerosis: a systematic review with a focus on regional differences, methodology, and clinical implications , 2020, Journal of Neurology.

[9]  V. Shaygannejad,et al.  Clinical Characteristics and Disability Progression of Early- and Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis , 2020, Journal of clinical medicine.

[10]  A. Vaitkus,et al.  Clinical and diagnostic features of patients with familial multiple sclerosis. , 2019, Medical hypotheses.

[11]  Sohila Khodakarim,et al.  Determining the Levels of Urbanization in Iran Using Hierarchical Clustering , 2019, Iranian journal of public health.

[12]  A. Ghezzi,et al.  Aging with multiple sclerosis: prevalence and profile of cognitive impairment , 2019, Neurological Sciences.

[13]  M. Ramanathan,et al.  Dietary and lifestyle factors in multiple sclerosis progression: results from a 5-year longitudinal MRI study , 2019, Journal of Neurology.

[14]  J. Lechner-Scott,et al.  Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis , 2018, Multiple sclerosis.

[15]  Narelle Warren,et al.  Multiple Sclerosis in the Asia Pacific Region: A Systematic Review of a Neglected Neurological Disease , 2018, Front. Neurol..

[16]  Marjan Mansourian,et al.  An 8-year study of people with multiple sclerosis in Isfahan, Iran: Association between environmental air pollutants and severity of disease , 2018, Journal of Neuroimmunology.

[17]  J. Menzin,et al.  Comorbidity in US patients with multiple sclerosis , 2018, Patient related outcome measures.

[18]  Jorge R Oksenberg,et al.  Multiple sclerosis genetics , 2018, Multiple sclerosis.

[19]  David H. Miller,et al.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.

[20]  Anders Larsson,et al.  Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2017, The Lancet Neurology.

[21]  J. Lechner-Scott,et al.  Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study , 2017, The Lancet Neurology.

[22]  J. Haselkorn,et al.  Mental Health Comorbidity in MS: Depression, Anxiety, and Bipolar Disorder , 2016, Current Neurology and Neuroscience Reports.

[23]  M. Magyari Gender differences in multiple sclerosis epidemiology and treatment response. , 2016, Danish medical journal.

[24]  S. Morrow,et al.  Depression and hypomania symptoms are associated with high dose corticosteroids treatment for MS relapses. , 2015, Journal of affective disorders.

[25]  Dashkovskiy Petr Ethnic and Religious Processes in Western Mongolia (Based on Social Research) , 2015 .

[26]  Jong-Jin Baik,et al.  Characteristics of the urban heat island in a high-altitude metropolitan city, Ulaanbaatar, Mongolia , 2013, Asia-Pacific Journal of Atmospheric Sciences.

[27]  G. Hallmans,et al.  Smoking as a risk factor for multiple sclerosis , 2013, Multiple sclerosis.

[28]  Kathleen F Villa,et al.  The cost burden of multiple sclerosis in the United States: a systematic review of the literature , 2013, Journal of medical economics.

[29]  W. Willett,et al.  Vitamin D, tuberculin skin test conversion, and latent tuberculosis in Mongolian school-age children: a randomized, double-blind, placebo-controlled feasibility trial. , 2012, The American journal of clinical nutrition.

[30]  D. Hafler,et al.  Fingolimod for multiple sclerosis. , 2012, The New England journal of medicine.

[31]  M Daumer,et al.  Age and disability accumulation in multiple sclerosis , 2011, Neurology.

[32]  M. Filippi,et al.  Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[33]  K. Dear,et al.  Sun exposure and vitamin D are independent risk factors for CNS demyelination , 2011, Neurology.

[34]  Y.‐H. Chen,et al.  Comorbidities amongst patients with multiple sclerosis: a population‐based controlled study , 2010, European journal of neurology.

[35]  F. Guillemin,et al.  Natural history of multiple sclerosis in a population‐based cohort , 2008, European journal of neurology.

[36]  L. Nyström,et al.  Smoking worsens the prognosis in multiple sclerosis , 2008, Multiple sclerosis.

[37]  S. Ferrando,et al.  Patient Health Questionnaire-9 to Screen for Depression in Outpatients With Multiple Sclerosis , 2007 .

[38]  C. Pozzilli,et al.  Effects of education level and employment status on HRQoL in early relapsing-remitting multiple sclerosis , 2007, Multiple sclerosis.

[39]  T. Pekmezović,et al.  Lifestyle Factors and Multiple Sclerosis: A Case-Control Study in Belgrade , 2006, Neuroepidemiology.

[40]  M. Melbye,et al.  Type 1 diabetes and multiple sclerosis: A Danish population-based cohort study. , 2006, Archives of neurology.

[41]  Christian Confavreux,et al.  Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[42]  D. Paty,et al.  Disability progression in multiple sclerosis is slower than previously reported , 2006, Neurology.

[43]  R. Fujinami,et al.  Converting relapsing remitting to secondary progressive experimental allergic encephalomyelitis (EAE) by ultraviolet B irradiation , 2005, Journal of Neuroimmunology.

[44]  L. Gunnarsson,et al.  Quality of life and impairment in patients with multiple sclerosis , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[45]  A. Ghezzi Clinical characteristics of multiple sclerosis with early onset , 2004, Neurological Sciences.

[46]  David R. Fraser,et al.  Vitamin D-deficiency in Asia , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[47]  Julián Benito-León,et al.  A review about the impact of multiple sclerosis on health-related quality of life , 2003, Disability and rehabilitation.

[48]  A. Janssens,et al.  A nxiety and depression influence the relation between disability status and quality of life in multiple sclerosis , 2003, Multiple sclerosis.

[49]  Maria Liguori,et al.  Age‐related disability in multiple sclerosis , 2002, Annals of neurology.

[50]  T. Sato,et al.  Corticosteroid-induced psychotic and mood disorders: diagnosis defined by DSM-IV and clinical pictures. , 2001, Psychosomatics.

[51]  M. Amato,et al.  Quality of life in multiple sclerosis: the impact of depression, fatigue and disability , 2001, Multiple sclerosis.

[52]  Lawrence Steinman,et al.  Multiple sclerosis: a two-stage disease , 2001, Nature Immunology.

[53]  H. Suzuki,et al.  Recurrent cases of corticosteroid-induced mood disorder: clinical characteristics and treatment. , 2000, The Journal of clinical psychiatry.

[54]  B. Weinshenker,et al.  Epidemiology of multiple sclerosis. , 1996, Neurologic clinics.

[55]  A. Stoudemire,et al.  Corticosteroid-induced delirium and dependency. , 1996, General hospital psychiatry.

[56]  J. Kurtzke Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[57]  T. Fog,et al.  [Multiple sclerosis; review]. , 1954, Maanedsskrift for praktisk laegegerning og social Medicin.

[58]  Erin L. Mazerolle,et al.  Diabetes and anxiety adversely affect cognition in multiple sclerosis. , 2019, Multiple sclerosis and related disorders.

[59]  Sahana K.R,et al.  Sunlight and vitamin D; A global perspective for health. , 2019 .

[60]  M. Cohen,et al.  [Depression in multiple sclerosis]. , 2009, Revue neurologique.

[61]  Michelle Stern,et al.  Aging with multiple sclerosis. , 2005, Physical medicine and rehabilitation clinics of North America.

[62]  R. Spitzer,et al.  The PHQ-9: validity of a brief depression severity measure. , 2001, Journal of general internal medicine.

[63]  G. Lista [The Babinski sign]. , 1966, Prensa Medica Argentina.